Ironwood Pharma (NASDAQ: IRWD) reported Q4 EPS of $0.30, $0.06 better than the analyst estimate of $0.24. Revenue for the quarter came in at $126.3 million versus the consensus estimate of $111.85 million.

“2019 brought us a catalyzing opportunity to become a GI-focused healthcare company dedicated to advancing the treatment of GI diseases and redefining the standard of care for millions of patients,” said Mark Mallon, chief executive officer of Ironwood. “To do this, we are executing on our strategy to drive LINZESS growth, advance our late-stage GI portfolio, and deliver sustainable profits. We made substantial progress in 2019 across each of these priorities and expect 2020 to be another pivotal year. We are already off to a strong start having settled all outstanding LINZESS patent litigation, and we look forward to continued momentum through strong growth of LINZESS, top-line data readouts from MD-7246 and IW-3718, and further revenue generation in 2020.”

GUIDANCE:

Ironwood Pharma sees FY2020 revenue of $360-380 million, versus the consensus of $391.25 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.